Leronlimab (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Leronlimab" in English language version.
refsWebsite
Global rank
English rank
1st place
1st place
low place
low place
5,225th place
4,062nd place
low place
low place
low place
low place
low place
low place
low place
low place
11th place
8th place
abstractsonline.com (Global: low place; English: low place)
- Dhody K, Kazempour K, Pourhassan N, Maddon PJ (2018). Primary Efficacy Results of PRO 140 SC in a Pivotal Phase 2b/3 Study in Heavily Treatment-Experienced HIV-1 Patients. Proceedings of the ASM Microbe. pp. 7–11. Retrieved 2018-04-19.
aidsmap.com (Global: low place; English: low place)
- Thaczuk D (21 September 2007). "ICAAC: Phase 1 study provides 'proof of concept' for PRO 140, a monoclonal CCR5 antibody". AIDSmap.com.
clinicaltrials.gov (Global: 5,225th place; English: 4,062nd place)
- Clinical trial number NCT03838367 for "Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC " at ClinicalTrials.gov
- Clinical trial number NCT03838367 for "Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC" at ClinicalTrials.gov
cytodyn.com (Global: low place; English: low place)
- "CytoDyn Announces Acquisition of PRO 140". CytoDyn Inc. October 17, 2012. Archived from the original on September 25, 2013. Retrieved December 18, 2012.
- "CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection :: CytoDyn Inc. (CYDY)". www.cytodyn.com. Archived from the original on 2020-04-04. Retrieved 2018-04-19.
- "CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018 :: CytoDyn Inc. (CYDY)". www.cytodyn.com. Archived from the original on 2018-09-03. Retrieved 2018-04-19.
- First Patient in CytoDyn's Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size, archived from the original on 2022-01-03, retrieved 2019-11-15
doi.org (Global: 2nd place; English: 2nd place)
- Jiao X, Wang M, Zhang Z, Li Z, Ni D, Ashton AW, et al. (January 2021). "Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy". Breast Cancer Research. 23 (1): 11. doi:10.1186/s13058-021-01391-1. PMC 7825185. PMID 33485378.
- Biswas P, Tambussi G, Lazzarin A (May 2007). "Access denied? The status of co-receptor inhibition to counter HIV entry". Expert Opinion on Pharmacotherapy. 8 (7): 923–933. doi:10.1517/14656566.8.7.923. PMID 17472538. S2CID 32675897.
- Pugach P, Ketas TJ, Michael E, Moore JP (August 2008). "Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors". Virology. 377 (2): 401–407. doi:10.1016/j.virol.2008.04.032. PMC 2528836. PMID 18519143.
- Li L, Tian JH, Yang K, Zhang P, Jia WQ (July 2014). "Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection". The Cochrane Database of Systematic Reviews. 2014 (7) CD008439. doi:10.1002/14651858.CD008439.pub3. PMC 7173721. PMID 25063928.
fda.gov (Global: 447th place; English: 338th place)
- "Statement on Leronlimab". U.S. Food and Drug Administration (FDA). 17 May 2021. Archived from the original on May 17, 2021. Retrieved 19 May 2021.
This article incorporates text from this source, which is in the public domain.
fool.com (Global: 4,183rd place; English: 2,600th place)
- Lawler B (2 May 2007). "Progenics' Intriguing Study Results". The Motley Fool.
hivandhepatitis.com (Global: low place; English: low place)
- Highleyman L (28 September 2007). "Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study". HIVandHepatitis.com. Archived from the original on 3 January 2022. Retrieved 29 December 2007.
nih.gov (Global: 4th place; English: 4th place)
pubmed.ncbi.nlm.nih.gov
- Jiao X, Wang M, Zhang Z, Li Z, Ni D, Ashton AW, et al. (January 2021). "Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy". Breast Cancer Research. 23 (1): 11. doi:10.1186/s13058-021-01391-1. PMC 7825185. PMID 33485378.
- Biswas P, Tambussi G, Lazzarin A (May 2007). "Access denied? The status of co-receptor inhibition to counter HIV entry". Expert Opinion on Pharmacotherapy. 8 (7): 923–933. doi:10.1517/14656566.8.7.923. PMID 17472538. S2CID 32675897.
- Pugach P, Ketas TJ, Michael E, Moore JP (August 2008). "Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors". Virology. 377 (2): 401–407. doi:10.1016/j.virol.2008.04.032. PMC 2528836. PMID 18519143.
- Li L, Tian JH, Yang K, Zhang P, Jia WQ (July 2014). "Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection". The Cochrane Database of Systematic Reviews. 2014 (7) CD008439. doi:10.1002/14651858.CD008439.pub3. PMC 7173721. PMID 25063928.
ncbi.nlm.nih.gov
- Jiao X, Wang M, Zhang Z, Li Z, Ni D, Ashton AW, et al. (January 2021). "Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy". Breast Cancer Research. 23 (1): 11. doi:10.1186/s13058-021-01391-1. PMC 7825185. PMID 33485378.
- Pugach P, Ketas TJ, Michael E, Moore JP (August 2008). "Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors". Virology. 377 (2): 401–407. doi:10.1016/j.virol.2008.04.032. PMC 2528836. PMID 18519143.
- Li L, Tian JH, Yang K, Zhang P, Jia WQ (July 2014). "Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection". The Cochrane Database of Systematic Reviews. 2014 (7) CD008439. doi:10.1002/14651858.CD008439.pub3. PMC 7173721. PMID 25063928.
poz.com (Global: low place; English: low place)
- Horn T (21 September 2007). "Single-Dose PRO 140 Has Lasting Effects". POZ.com.
progenics.com (Global: low place; English: low place)
- "Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation". Press release. Progenics Pharmaceuticals. 22 February 2006. Archived from the original on 2011-10-02.
- "PRO 140". Progenics Pharmaceuticals. Archived from the original on 2012-04-02. Retrieved 2007-12-29.
semanticscholar.org (Global: 11th place; English: 8th place)
api.semanticscholar.org
web.archive.org (Global: 1st place; English: 1st place)
- "CytoDyn Announces Acquisition of PRO 140". CytoDyn Inc. October 17, 2012. Archived from the original on September 25, 2013. Retrieved December 18, 2012.
- Highleyman L (28 September 2007). "Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study". HIVandHepatitis.com. Archived from the original on 3 January 2022. Retrieved 29 December 2007.
- "CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection :: CytoDyn Inc. (CYDY)". www.cytodyn.com. Archived from the original on 2020-04-04. Retrieved 2018-04-19.
- "CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018 :: CytoDyn Inc. (CYDY)". www.cytodyn.com. Archived from the original on 2018-09-03. Retrieved 2018-04-19.
- First Patient in CytoDyn's Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size, archived from the original on 2022-01-03, retrieved 2019-11-15
- "Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation". Press release. Progenics Pharmaceuticals. 22 February 2006. Archived from the original on 2011-10-02.
- "PRO 140". Progenics Pharmaceuticals. Archived from the original on 2012-04-02. Retrieved 2007-12-29.
- "Statement on Leronlimab". U.S. Food and Drug Administration (FDA). 17 May 2021. Archived from the original on May 17, 2021. Retrieved 19 May 2021. This article incorporates text from this source, which is in the public domain.